REG - BiVictriX Therapcts. - Director Dealing

Bivictrix TherapeuticsAnnouncement

13/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220913:nRSM1815Za&default-theme=true

RNS Number : 1815Z  BiVictriX Therapeutics PLC  13 September 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

 

Director Dealing

 

Alderley Park, 13 September 2022 BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, announces the following dealing in the Company's ordinary shares
of 1 pence each ("Ordinary Shares").

 

On 12 September 2022, Mr Iain Ross, the Company's Non-Executive Chairman,
purchased 105,000 Ordinary Shares at a weighted average price of 17.776 pence
each.

 

Following the transaction, Mr Ross is benefically interested in 505,000
Ordinary Shares, representing 0.76% of the Company's total issued share
capital.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 1.    Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                         Iain Ross
 2.    Reason for the Notification
 a)    Position/status                                              Non-Executive Chairman
 b)    Initial notification/Amendment                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                         BiVictriX Therapeutics plc
 b)    LEI                                                          213800ZI85IZNA6N3L53
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the Financial instrument, type of instrument  Ordinary Shares of 1 pence each

                                                                    GB00BNXH3K91
       Identification code
 b)    Nature of the transaction                                    Purchase of 105,000 Ordinary Shares
 c)    Price(s) and volume(s)

Price(s)               Volume(s)
                                                                    1.    17.7 pence       50,000

                                                                    2.    17.8 pence       30,000

                                                                    3.    17.9 pence       25,000

 d)    Aggregated information:                                      Price(s)                          Volume(s)

       -  Aggregated volume

       -  Price                                                     17,776 pence (weighted average)   105,000

 
 e)    Date of the transaction                                      12 September 2022
 f)    Place of the transaction                                     AIM, London Stock Exchange

d)

Aggregated information:

-  Aggregated volume

-  Price

 Price(s)                          Volume(s)

 17,776 pence (weighted average)   105,000

 

e)

Date of the transaction

12 September 2022

f)

Place of the transaction

AIM, London Stock Exchange

 

-Ends-

 

 For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Iain Ross, Chairman                                Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)  Tel: +44 (0) 20 3470 0470
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)         Tel: +44 (0) 20 7886 2500
 Rupert Dearden, Freddy Crossley, Emma Earl

 Consilium Strategic Communications
 Mary-Jane Elliott, Genevieve Wilson, Alex Gunter   Tel: +44 (0) 20 3709 5700

                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a new class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related harmful side effects. This
provides the opportunity for clinicians to give much higher, more effective
doses of treatment to patients without significantly harming the patient in
the process.

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
cancer-specific antigen pairs, or "twin antigens fingerprints", on tumour
cells, which are largely absent from healthy cells. Whereas this concept has
been validated in a clinical diagnostic setting to support the diagnosis and
monitoring of haematological cancers, it has not yet been widely used in a
therapeutic setting, where it offers the opportunity to be a game-changing
approach to cancer care.

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens fingerprints" across a broad range of cancer indications. The Company
is using these novel twin antigens to develop more effective and safer
therapeutics to target cancers that are expected to constitute orphan
indications and areas of high unmet medical need.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBIGDCIBBDGDD